Search

Your search keyword '"Halfvarson, Jonas"' showing total 28 results
Start Over Author "Halfvarson, Jonas" Journal inflammatory bowel diseases
28 results on '"Halfvarson, Jonas"'

4. The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study

Author

Holmgren, Johanna, Fröborg, Anna, Visuri, Isabella, Halfvarson, Jonas, Hjortswang, Henrik, Karling, Pontus, Myrelid, Pär, Olen, Ola, Ludvigsson, Jonas F., and Grip, Olof

Subjects
inflammatory bowel disease, anti-TNF, infections, biologics, real-world data, Infectious Medicine, Gastroenterologi, Gastroenterology, Immunology and Allergy, Infektionsmedicin, Gastroenterology and Hepatology
Abstract

Background Serious infections have been observed in patients with inflammatory bowel disease (IBD) on anti-TNF use—but to what extent these infections are due to anti-TNF or the disease activity per se is hard to disentangle. We aimed to describe how the rates of serious infections change over time both before and after starting anti-TNF in IBD. Methods Inflammatory bowel disease patients naïve to anti-TNF treatment were identified at 5 centers participating in the Swedish IBD Quality Register, and their medical records examined in detail. Serious infections, defined as infections requiring in-patient care, the year before and after the start of anti-TNF treatment were evaluated. Results Among 980 patients who started their first anti-TNF therapy between 1999 and 2016, the incidence rate of serious infections was 2.19 (95% CI,1.43-3.36) per 100 person years the year before and 2.11 (95% CI, 1.33-3.34) per 100 person years 1 year after treatment start. This corresponded to an incidence rate ratio 1 year after anti-TNF treatment of 0.97 (95% CI, 0.51-1.84). Compared with before anti-TNF therapy, the incidence of serious infection was significantly decreased more than 1 year after treatment (incidence rate ratio 0.56; 95% CI, 0.33-0.95; P = .03). Conclusions In routine clinical practice in Sweden, the incidence rate of serious infection among IBD patients did not increase with anti-TNF therapy. Instead, serious infections seemed to decrease more than 1 year after initiation of anti-TNF treatment.

Published
2022

12. Work Loss Before and After Diagnosis of Crohn’s Disease

Author

Everhov, Åsa H, primary, Khalili, Hamed, additional, Askling, Johan, additional, Myrelid, Pär, additional, Ludvigsson, Jonas F, additional, Halfvarson, Jonas, additional, Nordenvall, Caroline, additional, Neovius, Martin, additional, Söderling, Jonas, additional, and Olén, Ola, additional

Published
2018
Full Text
View/download PDF

13. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci

Author

Drobin, Kimi, primary, Assadi, Ghazaleh, additional, Hong, Mun-Gwan, additional, Andersson, Eni, additional, Fredolini, Claudia, additional, Forsström, Björn, additional, Reznichenko, Anna, additional, Akhter, Tahmina, additional, Ek, Weronica E, additional, Bonfiglio, Ferdinando, additional, Hansen, Mark Berner, additional, Sandberg, Kristian, additional, Greco, Dario, additional, Repsilber, Dirk, additional, Schwenk, Jochen M, additional, D’Amato, Mauro, additional, and Halfvarson, Jonas, additional

Published
2018
Full Text
View/download PDF

16. Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort

Author

Burisch, Johan, primary, Vardi, Hillel, additional, Pedersen, Natalia, additional, Brinar, Marko, additional, Cukovic-Cavka, Silvja, additional, Kaimakliotis, Ioannis, additional, Duricova, Dana, additional, Bortlik, Martin, additional, Shonová, Olga, additional, Vind, Ida, additional, Avnstrøm, Søren, additional, Thorsgaard, Niels, additional, Krabbe, Susanne, additional, Andersen, Vibeke, additional, Dahlerup, Jens F., additional, Kjeldsen, Jens, additional, Salupere, Riina, additional, Olsen, Jónger, additional, Nielsen, Kári R., additional, Manninen, Pia, additional, Collin, Pekka, additional, Katsanos, Konstantinnos H., additional, Tsianos, Epameinondas V., additional, Ladefoged, Karin, additional, Lakatos, Laszlo, additional, Bailey, Yvonne, additional, OʼMorain, Colm, additional, Schwartz, Doron, additional, Lupinacci, Guido, additional, De Padova, Angelo, additional, Jonaitis, Laimas, additional, Kupcinskas, Limas, additional, Turcan, Svetlana, additional, Barros, Louisa, additional, Magro, Fernando, additional, Lazar, Daniela, additional, Goldis, Adrian, additional, Nikulina, Inna, additional, Belousova, Elena, additional, Fernandez, Alberto, additional, Pineda, Juan R., additional, Almer, Sven, additional, Halfvarson, Jonas, additional, Tsai, Her-Hsin, additional, Sebastian, Shaji, additional, Friger, Michael, additional, Greenberg, Dan, additional, Lakatos, Peter L., additional, Langholz, Ebbe, additional, Odes, Selwyn, additional, and Munkholm, Pia, additional

Published
2015
Full Text
View/download PDF

17. Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe

Author

Burisch, Johan, primary, Pedersen, Natalia, additional, Cukovic-Cavka, Silvja, additional, Turk, Niksa, additional, Kaimakliotis, Ioannis, additional, Duricova, Dana, additional, Shonová, Olga, additional, Vind, Ida, additional, Avnstrøm, Søren, additional, Thorsgaard, Niels, additional, Krabbe, Susanne, additional, Andersen, Vibeke, additional, Dahlerup Jens, Frederik, additional, Kjeldsen, Jens, additional, Salupere, Riina, additional, Olsen, Jónger, additional, Nielsen, Kári Rubek, additional, Manninen, Pia, additional, Collin, Pekka, additional, Katsanos, Konstantinnos H., additional, Tsianos, Epameinondas V., additional, Ladefoged, Karin, additional, Lakatos, Laszlo, additional, Bailey, Yvonne, additional, O’Morain, Colm, additional, Schwartz, Doron, additional, Odes, Selwyn, additional, Martinato, Matteo, additional, Lombardini, Silvia, additional, Jonaitis, Laimas, additional, Kupcinskas, Limas, additional, Turcan, Svetlana, additional, Barros, Louisa, additional, Magro, Fernando, additional, Lazar, Daniela, additional, Goldis, Adrian, additional, Nikulina, Inna, additional, Belousova, Elena, additional, Fernandez, Alberto, additional, Hernandez, Vicent, additional, Almer, Sven, additional, Zhulina, Yaroslava, additional, Halfvarson, Jonas, additional, Tsai, Her-Hsin, additional, Sebastian, Shaji, additional, Lakatos, Peter Laszlo, additional, Langholz, Ebbe, additional, and Munkholm, Pia, additional

Published
2014
Full Text
View/download PDF

18. Subclinical Inflammation with Increased Neutrophil Activity in Healthy Twin Siblings Reflect Environmental Influence in the Pathogenesis of Inflammatory Bowel Disease

Author

Zhulina, Yaroslava, primary, Hahn-Strömberg, Victoria, additional, Shamikh, Alia, additional, Peterson, Christer G. B., additional, Gustavsson, Anders, additional, Nyhlin, Nils, additional, Wickbom, Anna, additional, Bohr, Johan, additional, Bodin, Lennart, additional, Tysk, Curt, additional, Carlson, Marie, additional, and Halfvarson, Jonas, additional

Published
2013
Full Text
View/download PDF

19. Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: A Retrospective Observational Study

Author

Sjöberg, Mats, primary, Walch, Andrea, additional, Meshkat, Mina, additional, Gustavsson, Anders, additional, Järnerot, Gunnar, additional, Vogelsang, Harald, additional, Hertervig, Erik, additional, Novacek, Gottfried, additional, Friis-Liby, Ingalill, additional, Blomquist, Lars, additional, Angelberger, Sieglinde, additional, Karlen, Per, additional, Grännö, Christer, additional, Vilien, Mogens, additional, Ström, Magnus, additional, Verbaan, Hans, additional, Hellström, Per M., additional, Dejaco, Clemens, additional, Magnuson, Anders, additional, Halfvarson, Jonas, additional, Reinisch, Walter, additional, and Tysk, Curt, additional

Published
2012
Full Text
View/download PDF

21. Analysis of 39 Crohnʼs Disease Risk loci in Swedish Inflammatory Bowel Disease Patients

Author

Törkvist, Leif, primary, Halfvarson, Jonas, additional, Ong, Rick T.H., additional, Lördal, Mikael, additional, Sjöqvist, Urban, additional, Bresso, Francesca, additional, Björk, Jan, additional, Befrits, Ragnar, additional, Löfberg, Robert, additional, Blom, Johannes, additional, Carlson, Marie, additional, Padyukov, Leonid, additional, DʼAmato, Mauro, additional, Seielstad, Mark, additional, and Pettersson, Sven, additional

Published
2010
Full Text
View/download PDF

22. PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease

Author

Zucchelli, Marco, primary, Torkvist, Leif, additional, Bresso, Francesca, additional, Halfvarson, Jonas, additional, Hellquist, Anna, additional, Anedda, Francesca, additional, Assadi, Ghazaleh, additional, Lindgren, Gunnar B., additional, Svanfeldt, Monika, additional, Janson, Martin, additional, Noble, Colin L., additional, Pettersson, Sven, additional, Lappalainen, Maarit, additional, Paavola-Sakki, Paulina, additional, Halme, Leena, additional, Färkkilä, Martti, additional, Turunen, Ulla, additional, Satsangi, Jack, additional, Kontula, Kimmo, additional, Löfberg, Robert, additional, Kere, Juha, additional, and DʼAmato, Mauro, additional

Published
2009
Full Text
View/download PDF

28. The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study.

Author

Holmgren J, Fröborg A, Visuri I, Halfvarson J, Hjortswang H, Karling P, Myrelid P, Olén O, Ludvigsson JF, and Grip O

Subjects
Humans, Tumor Necrosis Factor-alpha therapeutic use, Retrospective Studies, Incidence, Tumor Necrosis Factor Inhibitors therapeutic use, Inflammatory Bowel Diseases drug therapy
Abstract

Background: Serious infections have been observed in patients with inflammatory bowel disease (IBD) on anti-TNF use-but to what extent these infections are due to anti-TNF or the disease activity per se is hard to disentangle. We aimed to describe how the rates of serious infections change over time both before and after starting anti-TNF in IBD., Methods: Inflammatory bowel disease patients naïve to anti-TNF treatment were identified at 5 centers participating in the Swedish IBD Quality Register, and their medical records examined in detail. Serious infections, defined as infections requiring in-patient care, the year before and after the start of anti-TNF treatment were evaluated., Results: Among 980 patients who started their first anti-TNF therapy between 1999 and 2016, the incidence rate of serious infections was 2.19 (95% CI,1.43-3.36) per 100 person years the year before and 2.11 (95% CI, 1.33-3.34) per 100 person years 1 year after treatment start. This corresponded to an incidence rate ratio 1 year after anti-TNF treatment of 0.97 (95% CI, 0.51-1.84). Compared with before anti-TNF therapy, the incidence of serious infection was significantly decreased more than 1 year after treatment (incidence rate ratio 0.56; 95% CI, 0.33-0.95; P = .03)., Conclusions: In routine clinical practice in Sweden, the incidence rate of serious infection among IBD patients did not increase with anti-TNF therapy. Instead, serious infections seemed to decrease more than 1 year after initiation of anti-TNF treatment., (© 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results